A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public

Amelia K. Smit; David Espinoza; Ainsley J. Newson; Rachael L. Morton; Georgina Fenton; Lucinda Freeman; Kate Dunlop; Phyllis N. Butow; Matthew H. Law; Michael G. Kimlin; Louise A. Keogh; Suzanne J. Dobbinson; Judy Kirk; Peter A. Kanetsky; Graham J. Mann; Anne E. Cust

doi:10.1158/1055-9965.EPI-16-0395

A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public

Amelia K. Smit, David Espinoza, Ainsley J. Newson, Rachael L. Morton, Georgina Fenton, Lucinda Freeman, Kate Dunlop, Phyllis N. Butow, Matthew H. Law, Michael G. Kimlin, Louise A. Keogh, Suzanne J. Dobbinson, Judy Kirk, Peter A. Kanetsky, Graham J. Mann, Anne E. Cust^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

39 Citations (Scopus)

Abstract

Background:

Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors.

Methods:

We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (non personalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values.

Results:

Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3months (0.40;95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress.

Conclusions:

Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. Impact: Genomic risk information has potential as a melanoma prevention strategy.

Original language	English
Pages (from-to)	212-221
Number of pages	10
Journal	Cancer Epidemiology Biomarkers and Prevention
Volume	26
Issue number	2
DOIs	https://doi.org/10.1158/1055-9965.EPI-16-0395
Publication status	Published - 1 Feb 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1055-9965.EPI-16-0395

Cite this

Smit, A. K., Espinoza, D., Newson, A. J., Morton, R. L., Fenton, G., Freeman, L., Dunlop, K., Butow, P. N., Law, M. H., Kimlin, M. G., Keogh, L. A., Dobbinson, S. J., Kirk, J., Kanetsky, P. A., Mann, G. J., & Cust, A. E. (2017). A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public. Cancer Epidemiology Biomarkers and Prevention, 26(2), 212-221. https://doi.org/10.1158/1055-9965.EPI-16-0395

@article{9ef72ed98b8740718799384c04293bc0,

title = "A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public",

abstract = "Background: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors.Methods: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (non personalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values. Results: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3months (0.40;95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress. Conclusions: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. Impact: Genomic risk information has potential as a melanoma prevention strategy.",

author = "Smit, {Amelia K.} and David Espinoza and Newson, {Ainsley J.} and Morton, {Rachael L.} and Georgina Fenton and Lucinda Freeman and Kate Dunlop and Butow, {Phyllis N.} and Law, {Matthew H.} and Kimlin, {Michael G.} and Keogh, {Louise A.} and Dobbinson, {Suzanne J.} and Judy Kirk and Kanetsky, {Peter A.} and Mann, {Graham J.} and Cust, {Anne E.}",

note = "Publisher Copyright: {\textcopyright} 2016 American Association for Cancer Research.",

year = "2017",

month = feb,

day = "1",

doi = "10.1158/1055-9965.EPI-16-0395",

language = "English",

volume = "26",

pages = "212--221",

journal = "Cancer Epidemiology Biomarkers and Prevention",

issn = "1055-9965",

publisher = "AMER ASSOC CANCER RESEARCH",

number = "2",

}

Smit, AK, Espinoza, D, Newson, AJ, Morton, RL, Fenton, G, Freeman, L, Dunlop, K, Butow, PN, Law, MH, Kimlin, MG, Keogh, LA, Dobbinson, SJ, Kirk, J, Kanetsky, PA, Mann, GJ & Cust, AE 2017, 'A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public', Cancer Epidemiology Biomarkers and Prevention, vol. 26, no. 2, pp. 212-221. https://doi.org/10.1158/1055-9965.EPI-16-0395

A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public. / Smit, Amelia K.; Espinoza, David; Newson, Ainsley J. et al.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 2, 01.02.2017, p. 212-221.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public

AU - Smit, Amelia K.

AU - Espinoza, David

AU - Newson, Ainsley J.

AU - Morton, Rachael L.

AU - Fenton, Georgina

AU - Freeman, Lucinda

AU - Dunlop, Kate

AU - Butow, Phyllis N.

AU - Law, Matthew H.

AU - Kimlin, Michael G.

AU - Keogh, Louise A.

AU - Dobbinson, Suzanne J.

AU - Kirk, Judy

AU - Kanetsky, Peter A.

AU - Mann, Graham J.

AU - Cust, Anne E.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors.Methods: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (non personalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values. Results: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3months (0.40;95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress. Conclusions: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. Impact: Genomic risk information has potential as a melanoma prevention strategy.

AB - Background: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors.Methods: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (non personalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values. Results: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0-10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [-16%; 95% confidence interval (CI), -43% to 24%] and sun protection index (0.05; 95% CI, -0.07 to 0.18). There was increased confidence identifying melanoma at 3months (0.40;95% CI, 0.10-0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer-related worry or psychologic distress. Conclusions: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public. Impact: Genomic risk information has potential as a melanoma prevention strategy.

UR - http://www.scopus.com/inward/record.url?scp=85013630762&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0395

DO - 10.1158/1055-9965.EPI-16-0395

M3 - Article

C2 - 27702805

AN - SCOPUS:85013630762

SN - 1055-9965

VL - 26

SP - 212

EP - 221

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

IS - 2

ER -

A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this